Trials / Conditions / Metabolic Dysfunction-associated Steatohepatitis (MASH)

Metabolic Dysfunction-associated Steatohepatitis (MASH)

18 registered clinical trials studyying Metabolic Dysfunction-associated Steatohepatitis (MASH) — 12 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD NCT07313007	Hospices Civils de Lyon	N/A
Recruiting	A Study of CS060380 Tablets in Patients With MASH and Obesity NCT07466017	Cascade Pharmaceuticals, Inc	Phase 2
Not Yet Recruiting	Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults NCT07331545	Qilu Pharmaceutical Co., Ltd.	Phase 1
Completed	A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the NCT07201831	Novo Nordisk A/S	—
Recruiting	A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) NCT07145151	The United Bio-Technology (Hengqin) Co., Ltd.	Phase 2
Recruiting	Evaluation of Miricorilant on Liver Fat in Patients With MASLD NCT06947304	Corcept Therapeutics	Phase 1
Recruiting	A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) NCT06937749	Innovent Biologics (Suzhou) Co. Ltd.	Phase 2
Not Yet Recruiting	To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH NCT07016633	Changchun Intellicrown Pharmaceutical Co. LTD	Phase 1 / Phase 2
Recruiting	Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study NCT07188220	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	—
Not Yet Recruiting	Clinical Classification of MAFLD Based Liver Biopsy NCT06795646	Beijing Friendship Hospital	—
Completed	A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH NCT06675929	Boehringer Ingelheim	Phase 2
Recruiting	LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Mod NCT06632444	Boehringer Ingelheim	Phase 3
Completed	Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM NCT06492330	Shanghai Jiao Tong University School of Medicine	N/A
Recruiting	Fibrosis Lessens After Metabolic Surgery NCT06374875	Ali Aminian	Phase 4
Active Not Recruiting	A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfun NCT06108219	Corcept Therapeutics	Phase 2
Recruiting	A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfuncti NCT05519475	Regeneron Pharmaceuticals	Phase 2
Active Not Recruiting	A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated NCT05395481	Eli Lilly and Company	Phase 1
Completed	New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) NCT06647095	General University Hospital, Prague	—